Multiple Sclerosis News Today2h
Fatigue significantly contributes to impaired well-being in MS: Study
Nearly 50% of MS patients report pronounced fatigue, which has a significantly negative impact on their well-being, a Finnish ...
En Pareja on MSN4h
What is Multiple Sclerosis? The Condition Yolanda Andrade is Battling
After much speculation about her health, it has been revealed that Yolanda Andrade is dealing with multiple sclerosis. So, ...
High‑dose vitamin D significantly reduces disease activity in early multiple sclerosis onset, clinical trial finds
Researchers from CHU Nîmes, Université Montpellier, and multiple MS centers in France have found that oral cholecalciferol in ...
Multiple Sclerosis News Today2h
What I’ve learned from my aunt, who has secondary progressive MS
Chris Delemater says he's learned a lot from his aunt, Jenn Powell, who has MS, particularly about self-love and acceptance.
Sanofi gets priority review for its multiple sclerosis treatment by FDA
Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review to the regulatory submission of tolebrutinib ...
Non-profit raising awareness about Mutiple Sclerosis during Walk & Roll event
The non-profit hopes to promote physical, emotional, and social well-being for people with MS. MS is an autoimmune disease that affects the brain and spinal cord, and Shannon Tanzer, the president of ...
Applied Clinical Trials Online5h
Results of Phase III HERCULES, GEMINI 1 and 2 Trials Lead to FDA Priority Review for Tolebrutinib for Non-Relapsing Secondary Progressive MS
FDA grants Priority Review status to Sanofi's tolebrutinib for the treatment of non-relapsing secondary progressive multiple ...
Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to ...
Spreading Awareness of Multiple Sclerosis
March is regonized as multiple sclerosis awareness month. One woman is shining a light on MS and sharing a message of hope ...
pharmaphorum6h
FDA starts review of Sanofi's MS hope tolebrutinib
The FDA review – which is due to be completed by 28th September – revolves around the results of the HERCULES trial which ...
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
Sanofi: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to ...